Interleukin 1α and interleukin 18 in patients with vitiligo - Results of a case-control study.

[1]  A. Kaszuba,et al.  Increased Serum Levels of IFN-γ, IL-1β, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo , 2020, Oxidative medicine and cellular longevity.

[2]  Jianyun Lu,et al.  Roles of inflammation factors in melanogenesis , 2020, Molecular medicine reports.

[3]  L. Larue,et al.  Molecular and cellular basis of depigmentation in vitiligo patients , 2019, Experimental dermatology.

[4]  A. Bishnoi,et al.  Clinical and Molecular Aspects of Vitiligo Treatments , 2018, International journal of molecular sciences.

[5]  M. Mansuri,et al.  Association of interleukin 1 receptor antagonist intron 2 variable number of tandem repeats polymorphism with vitiligo susceptibility in Gujarat population , 2018, Indian journal of dermatology, venereology and leprology.

[6]  M. Picardo,et al.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy , 2018, Clinical Reviews in Allergy & Immunology.

[7]  Jing Shang,et al.  Cross-talk between interferon-gamma and interleukin-18 in melanogenesis. , 2016, Journal of photochemistry and photobiology. B, Biology.

[8]  K. Ezzedine,et al.  A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children , 2016, Pediatrics.

[9]  G. Mohammed,et al.  Highlights in pathogenesis of vitiligo. , 2015, World journal of clinical cases.

[10]  M. Mansuri,et al.  Association of Neuropeptide Y (NPY), Interleukin-1B (IL1B) Genetic Variants and Correlation of IL1B Transcript Levels with Vitiligo Susceptibility , 2014, PloS one.

[11]  J. Schwartz,et al.  Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells , 2013, The Indian journal of medical research.

[12]  Jing Shang,et al.  Interleukin-18 augments growth ability of primary human melanocytes by PTEN inactivation through the AKT/NF-κB pathway. , 2013, The international journal of biochemistry & cell biology.

[13]  F. Guarneri,et al.  Quality of life in vitiligo patients , 2012, Dermatologic therapy.

[14]  M. Picardo,et al.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference , 2012, Pigment cell & melanoma research.

[15]  O. Shaker,et al.  Role of interleukin‐17 in the pathogenesis of vitiligo , 2011, Clinical and experimental dermatology.

[16]  P. Coulie,et al.  Interleukins 1α and 1β secreted by some melanoma cell lines strongly reduce expression of MITF‐M and melanocyte differentiation antigens , 2010, International journal of cancer.

[17]  W. Yun,et al.  JNK pathway is required for TNCB-induced IL-18 expression in murine keratinocytes. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[18]  Connie B. Lin,et al.  The role of keratinocyte growth factor in melanogenesis: a possible mechanism for the initiation of solar lentigines , 2009, Experimental dermatology.

[19]  M. Wittmann,et al.  IL-18 and skin inflammation. , 2009, Autoimmunity reviews.

[20]  M. Picardo,et al.  The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. , 2007, Pigment cell research.

[21]  Michael U. Martin,et al.  Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. , 2002, Biochimica et biophysica acta.

[22]  B. A. Gilchrest,et al.  Regulation of keratinocyte growth factor gene expression in human skin fibroblasts. , 1996, Journal of dermatological science.

[23]  S. Kondo,et al.  Differential modulation of interleukin‐1α (IL‐1α) and interleukin‐1β(IL‐1β in human epidermal keratinocytes by UVB , 1994 .

[24]  C. March,et al.  cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. , 1988, Science.